Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ
The deal has Sanofi paying $105 per share in cash. Source: BioSpace
Bay Area's Eureka Therapeutics Banks $60M
Acorn Pacific Ventures led the round, with participation from GP Capital and all existing major investors. Source: BioSpace
What You Need to Know About Indalo Therapeutics
Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics. Source: BioSpace
Astellas, Vical's Lead CMV Vaccine Flunks Key Phase III Study
The drug did not meet its primary or secondary endpoints in the Phase 3 HELIOS clinical trial. Source: BioSpace
Most-Wanted Life Sciences Employers in Genetown
Life sciences professionals don't have to look far for opportunity in Genetown. Source: BioSpace
New York's Tyme Jumps as Pancreatic Cancer Drug Shines in Early-Stage Study
The data was presented at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, Calif. today. Source: BioSpace
Why This Seattle Biotech Could be an M&A Target
Immune Design is a clinical-stage immunotherapy company. Source: BioSpace
Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei
Dr. Marshall will leave Sosei at the end of February 2018. Source: BioSpace
What You Need to Know About Jecure Therapeutics
Jecure Therapeutics, based in San Diego, stated operations in mid-2016 with a focus on NASH and liver fibrosis. Source: BioSpace
Teva's Job Cuts Hit 208 Philadelphia Employees
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue…
- Go to the previous page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- …
- 288
- Go to the next page